Fasting could amplify breast cancer treatment by triggering key hormonal and genetic changes in tumor cells. Estrogen receptor–positive breast cancer, the most common form worldwide, is typically treated with endocrine therapies that block or lessen estrogen’s effects. While these drugs are powerful, some tumors eventually become resistant after years of treatment, prompting researchers to seek strategies that boost effectiveness and extend the period before resistance develops. Diet is gaining attention as a potential contributor, with several studies suggesting that controlled short-term fasting can make cancer cells more responsive to therapy. The latest Nature study expands these ideas, showing that fasting can prompt hormonal and genetic shifts in tumor cells that enhance the impact of endocrine therapy, potentially paving the way for safer, more practical combination approaches in the near future.
Fasting enhances breast cancer treatment when paired with endocrine therapy. Most breast cancers rely on the estrogen receptor to drive growth, and tamoxifen is designed to block this pathway. The new findings indicate that severe, intermittent fasting can increase the drugs’ effectiveness by altering the cancer cells’ genetics and hormonal signals. In animal experiments, tumors in fasting mice treated with tamoxifen shrank substantially more than tumors in mice given tamoxifen alone.
A central explanation lies in fasting’s effect on the tumor epigenome. Epigenetics involves chemical markers that switch genes on or off. Fasting produced widespread epigenetic changes, effectively “re-educating” breast cancer cells so they became more susceptible to treatment and less able to support tumor growth.
The Glucocorticoid Receptor takes a leading role. A major takeaway from the study is the involvement of the Glucocorticoid Receptor, which is activated by body-produced hormones such as cortisol during fasting. When this receptor is activated inside cancer cells, a set of genes that suppress tumor growth is turned on. At the same time, fasting reduces activity of the AP-1 protein group, which ordinarily helps cancer cells multiply. As a result, tumor cells become less resistant to therapy and less capable of surviving. Notably, removing the glucocorticoid receptor from cancer cells abolished the enhanced response to tamoxifen observed with fasting, indicating this receptor drives the improved outcome.
The progesterone receptor adds another protective layer. Fasting also increased progesterone levels in mice and in humans following a fasting-mimicking regimen, activating the progesterone receptor, which can hinder tumor growth in estrogen receptor–positive breast cancer. Although the glucocorticoid receptor remains the primary focus, the progesterone receptor appears to contribute to anti-tumor effects as well.
A brief fasting-mimicking diet shows similar benefits in patients. In a small group of hormone receptor–positive breast cancer patients who combined a short fasting-mimicking diet with endocrine therapy, blood tests revealed elevated cortisol and progesterone levels, paralleling the animal data. Biopsies after the diet showed stronger glucocorticoid receptor gene activity alongside lower indicators of cell division in tumor tissue. These findings support the idea that even short, controlled dietary interventions can provoke meaningful biological changes within breast tumors.
Steroid drugs may imitate fasting’s effects. The researchers also explored whether the benefits of fasting could be replicated without actual fasting. They used dexamethasone, a synthetic glucocorticoid commonly given to reduce inflammation, alongside tamoxifen, and found it could elicit a comparable anti-tumor response to fasting. Tumors shrank more and remained responsive to treatment longer even after therapy ended. This points toward a potential future where steroid-based regimens, under careful supervision, could offer a more feasible alternative for patients who struggle with long fasting periods. However, thorough safety investigations are essential before any such approach is approved.
Implications for future breast cancer treatment. The study suggests that to improve endocrine therapy effectiveness in estrogen receptor–positive breast cancer, attention should turn to the glucocorticoid receptor. Steroid-based strategies might mimic fasting’s beneficial effects, but more evidence is needed to establish safety and efficacy. Nevertheless, the findings provide a compelling signal that targeted metabolic and hormonal interventions could help overcome treatment resistance—a persistent challenge in breast cancer therapy—and guide the development of safer, more effective combination treatments in the years ahead.
What this could mean for you: fasting or fasting-mimicking approaches may become part of a broader strategy to boost endocrine therapies in estrogen receptor–positive breast cancer, potentially delaying resistance and improving outcomes. For patients and clinicians, the key questions moving forward are about who might benefit most, the optimal timing and duration of such interventions, and how to balance potential benefits with safety. Could a personalized, hormone-targeted approach—using fasting or carefully controlled steroids—be the next step in making endocrine therapy more durable? Share your thoughts and experiences in the comments.
